Business Context and Reporting Period
This Form 8-K was filed by Processa Pharmaceuticals, Inc. (formerly Heatwurx, Inc.) on October 23, 2017. The report details a corporate restructuring effective on that date, including a name change and a reverse stock split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Name Change: The company officially changed its name from Heatwurx, Inc. to Processa Pharmaceuticals, Inc. via an amendment to its Certificate of Incorporation.
- Reverse Stock Split: Shareholders approved a 7-for-1 reverse stock split, combining seven issued and outstanding shares into one share, rounded up to the next whole share.
- Trading Symbol: The company requested FINRA approval to implement the name change and reverse split. The trading symbol had previously been approved for change from "HUWX" to "PCSA" following the acquisition of Promet Therapeutics, LLC assets.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural announcement of the name change and stock split.
Investor Verification Checklist
- Confirm the effective date of the 7-for-1 reverse stock split and its impact on share count.
- Verify the implementation of the new trading symbol "PCSA" on major exchanges.
- Review the amended Certificate of Incorporation (Exhibit 3.1) for any other bylaw changes.
- Check subsequent filings for financial data related to the Promet Therapeutics acquisition.